Non Small Cell Lung Cancer (NSCLC)

Stage IV / Metastatic - 2nd Line - Immunotherapy

Tumor-Infiltrating Lymphocytes (TIL)

VAR0241
Phase III
Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOV-4031) in Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer

PI: Betof
Sponsor: Iovance Biotherapeutics, Inc.

Progressed on Immunotherapy

ECOG-ACRIN-EA5191
Randomized Phase II Trial of Cabozantinib & Cabozantinib + Nivolumab vs Standard Chemotherapy in Previously Treated Non-Squamous NSCLC

PI: Neal
Sponsor: ECOG-ACRIN

Without Actionable Genomic Alterations

LUN0131
Phase II
Dose-Escalation & Expansion Study of the Safety & Efficacy of XL092 in Combo w/ Immuno-Oncology Agents in Unresectable Advanced or Metastatic Solid Tumors

PI: Neal
Sponsor: Exelixis, Inc.